natgillin/translations-raw huggingface dataset:
• altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive
- promijenjen ili povećan seksualni interes i ponašanje koje znatno zabrinjava Vas ili druge, na primjer, povećani seksualni poriv,
If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.
Ako ste zaboravili uzeti Aripiprazol Accord Ako ste propustili uzeti dozu, uzmite je čim se sjetite, ali nemojte uzeti dvije doze u jednom danu.
Sage house, 319 Pinner road, North Harrow, Middlesex HA1 4HF, United Kingdom
Sage house, 319 Pinner road, North Harrow, Middlesex HA1 4HF, Ujedinjeno Kraljevstvo
Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
Neiskorišteni lijek ili otpadni materijal mora se zbrinuti sukladno lokalnim propisima.
Try to take Aripiprazole Accord at the same time each day.
Accord svaki dan u isto vrijeme.
If you have the impression that the effect of this medicine is too strong or too weak, talk to your doctor or pharmacist.
Ako imate dojam da je učinak ovog lijeka prejak ili preslab, obratite se svom liječniku ili ljekarniku.
Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole.
Bolesnici mogu osjetiti pojačane porive, osobito za kockanjem, te nemogućnost kontroliranja tih poriva dok uzimaju aripiprazole.
Before treatment with Aripiprazole Accord, tell your doctor if you suffer from
Prije liječenja lijekom Aripiprazol Accord, obavijestite svog liječnika ako bolujete od
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ALUMINIUM/ALUMINIUM BLISTERS
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP ALUMINIJ/ALUMINIJ BLISTERI
If you are taking ARIPIPRAZOLE ACCORD, your doctor will discuss with you whether you should breast-feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding.
Ako uzimate Aripiprazol Accord, Vaš će liječnik razgovarati s Vama o tome trebate li dojiti uzimajući u obzir korist liječenja za Vas i korist dojenja za dijete.
In adults it also prevents this condition from returning in patients who have responded to the treatment with this medicine.
Također sprječava povratak takvog stanja u odraslih bolesnika koji su prethodno imali odgovor na terapiju ovim lijekom.
14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets
14 x 1 tableta 28 x 1 tableta 49 x 1 tableta 56 x 1 tableta 98 x 1 tableta
The point estimate of the hazard ratio (HR) was 0.461 (95% confidence interval, 0.242-0.879) in the full population.
Točkovna procjena omjera hazarda (HR) iznosila je 0,461 (95 % interval pouzdanosti: 0,242-0,879) u ukupnoj populaciji.
Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non genotoxic.
Na temelju rezultata punog raspona standardnih testova genotoksičnosti, smatra se da aripiprazol nije genotoksičan.
(for 100's count) Do not throw away any medicines via wastewater or household waste.
Nikada nemojte nikakve lijekove bacati u otpadne vode ili kućni otpad.
The European Medicines Agency has deferred the obligation to submit the results of studies with aripiprazole in one or more subsets of the paediatric population in the treatment of schizophrenia and in the treatment of bipolar affective disorder (see section 4.2 for information on paediatric use).
Europska agencija za lijekove je odgodila obvezu podnošenja rezultata ispitivanja Aripiprazolaripiprazola u jednoj ili više podskupina pedijatrijske populacije u liječenju shizofrenije te u liječenju bipolarnog afektivnog poremećaja (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
• Tell your doctor if you experience any of these behaviours; he/she will discuss ways of managing or reducing the symptoms.
Obavijestite liječnika ako primijetite neko od ovih ponašanja, tako da možete raspraviti o načinima njihova zbrinjavanja ili smanjivanja simptoma.
Aripiprazole Accord contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
Accord sadrži djelatnu tvar aripiprazol i pripada skupini lijekova koji se zovu antipsihotici.
Taking ARIPIPRAZOLE ACCORD with some medicines may mean the doctor will need to change your dose of ARIPIPRAZOLE ACCORD or the other medicines.
Accord s nekim lijekovima može značiti da će Vam liječnik morati promijeniti dozu lijeka Aripiprazol
The following symptoms may occur in newborn babies, of mothers that have used this medicine in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Sljedeći simptomi se mogu javiti u novorođenčadi majki koje su uzimale ovaj lijek u posljednjem tromjesečju (posljednja tri mjeseca trudnoće): tresavica, ukočenost i/ili slabost mišića, pospanost, uznemirenost, tegobe s disanjem i poteškoće s hranjenjem.
Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolesnici s rijetkim nasljednim poremećajima nepodnošenja galaktoze, nedostatkom laktaze ili malapsorpcijom glukoze i galaktoze ne smiju uzimati ovaj lijek.
What you need to know before you take Aripiprazole Accord
Što morate znati prije nego počnete uzimati Aripiprazol Accord
However, the estimation of the HR for the younger (13-14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect.
Međutim, procjena HR-a u mlađoj (u dobi od 13 do 14 godina) skupini nije bila precizna zbog manjeg broja ispitanika u toj skupini (aripiprazol, n = 29; placebo, n = 12), a interval pouzdanosti ove procjene (u rasponu od 0,151 do 1,628) nije dopustio donošenje zaključka o prisutnosti terapijskog učinka.
Aripiprazole Accord is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).
Accord se ne preporučuje za primjenu u bolesnika sa shizofrenijom mlađih od 15 godina, zbog nedostatnih podataka o sigurnosti i djelotvornosti (vidjeti dijelove 4.8 i 5.1).
Always take this medicine exactly as your doctor or pharmacist has told you.
Kako uzimati Aripiprazol Accord Uvijek uzmite ovaj lijek točno onako kako Vam rekli Vaš liječnik ili ljekarnik.
Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.
Accord je indiciran za liječenje shizofrenije u odraslih i adolescenata u dobi od 15 i više godina.
Treatment should be initiated at 2 mg (using aripiprazole oral solution 1 mg/ml) for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg.
Liječenje se mora započeti dozom od 2 mg (koristeći Aripiprazoloralnu otopinu aripiprazola od 1 mg/ml) tijekom prva 2 dana, a potom titrirati do 5 mg tijekom sljedeća 2 dana kako bi se postigla preporučena dnevna doza od 10 mg.
Aripiprazole Accord is effective in a dose range of 10 to 30 mg/day.
Aripiprazol Accord je učinkovit u rasponu doza od 10 do 30 mg/dan.
This medicine is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Ovaj se lijek koristi za liječenje odraslih osoba te adolescenata u dobi od 13 godina i starijih koji boluju od stanja čiji su simptomi “povišeno” raspoloženje, pretjerana količina energije, potreba za manjom količinom sna nego obično, vrlo brz govor i ubrzan tijek misli te ponekad teška razdražljivost.
What Aripiprazole Accord is and what it is used for What you need to know before you take Aripiprazole Accord How to take Aripiprazole Accord Possible side effects 5 How to store Aripiprazole Accord Contents of the pack and other information
Accord i za što se koristi Što morate znati prije nego počnete uzimati Aripiprazol Accord Kako uzimati Aripiprazol Accord Moguće nuspojave
If you realise you have taken more Aripiprazole Accord than your doctor has recommended (or if someone else has taken some of your Aripiprazole Accord), contact your doctor right away.
Accord nego što Vam je preporučio liječnik (ili ako je neka druga osoba uzela dio Vašeg lijeka Aripiprazol Accord), odmah o tome obavijestite svog liječnika.
In contrast the 95% confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.
Nasuprot tome, 95%-tni interval pouzdanosti za HR u starijoj podskupini (aripiprazol, n = 69; placebo, n = 36) iznosio je 0,242 do 0,879 pa se stoga moglo zaključiti da je u starijih bolesnika bio prisutan terapijski učinak.
Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol.
Stvarni rezultati na ocjenskim ljestvicama, uključujući PANSS i Montgomery-Asberg ocjensku skalu depresije, koji su se koristili kao sekundarne mjere ishoda, pokazali su značajno poboljšanje u odnosu na haloperidol.
The most commonly reported adverse reactions in placebo-controlled trials are akathisia and nausea each occurring in more than 3% of patients treated with oral aripiprazole.
Najčešće prijavljene nuspojave u placebom kontroliranim ispitivanjima su akatizija i mučnina, od kojih se svaka javlja u više od 3 % bolesnika liječenih oralnim aripiprazolom.
Potential for aripiprazole to affect other medicinal products In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
U kliničkim ispitivanjima, doze aripiprazola od 10 do 30 mg/dan nisu imale značajnog učinka na metabolizam supstrata CYP2D6 (omjer dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ni CYP3A4 (dekstrometorfan).
Other medicines and Aripiprazole Accord
Drugi lijekovi i Aripiprazol Accord
Developmentaltoxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose.
Razvojna toksičnost, uključujući odgođenu fetalnu osifikaciju ovisnu o dozi i moguće teratogene učinke, bila je primijećena u štakora pri dozama koje su izazvale subterapijsku izloženost (na temelju AUC-a) i u kunića pri dozama koje su izazvale izloženost 3 i 11 puta veću od srednje vrijednosti AUC-a u stanju dinamičke ravnoteže uz maksimalnu preporučenu kliničku dozu.
Do not use this medicine after the expiry date which is stated on the blister or label and on the carton after EXP.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na blisteru ili naljepnici i kutiji iza oznake „Rok valjanosti“.
These medicines may increase the risk of side effects or reduce the effect of ARIPIPRAZOLE ACCORD; if you get any unusual symptom taking any of these medicines together with ARIPIPRAZOLE ACCORD you should see your doctor.
Ti lijekovi mogu povećati rizik od nuspojava ili smanjiti učinak lijeka Aripiprazol Accord; ako dobijete neki neobični simptom dok uzimate ove lijekove zajedno s lijekom Aripiprazol Accord, trebate se obratiti liječniku.
Schizophrenia: in a long term 52-week controlled trial, aripiprazole-treated patients had an overalllower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %).
Shizofrenija: u dugotrajnom kontroliranom ispitivanju u trajanju od 52 tjedna, bolesnici liječeni aripiprazolom imali su nižu ukupnu incidenciju (25,8 %) EPS-a uključujući parkinsonizam, akatiziju, distoniju i diskineziju u usporedbi s onima liječenima haloperidolom (57,3 %).
In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer's disease, patients treated with aripiprazole were at increased risk of death compared to placebo.
U tri placebom kontrolirana ispitivanja aripiprazola u starijih bolesnika (n = 938; prosječna dob: 82,4 godine; raspon: 56-99 godina) s psihozom koja je bila povezana s Alzheimerovom bolešću, bolesnici liječeni aripiprazolom imali su povišen rizik od smrti u odnosu na bolesnike koji su primali placebo.
These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with ARIPIPRAZOLE ACCORD, you should see your doctor.
Ovi lijekovi mogu povećati rizik od nuspojava; ako dobijete ikakve neobične simptome dok uzimate neki od ovih lijekova zajedno s lijekom Aripiprazol Accord, trebate se obratiti liječniku.
- 30 day (for HDPE 30's count) - 100 day (for HDPE 100's count)
Rok valjanosti nakon prvog otvaranja: - 30 dana (za HDPE s 30 tableta) - 100 dana (za HDPE sa 100 tableta)
According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).
Pušenje S obzirom na metabolički put aripiprazola nije potrebna prilagodba doze u pušača (vidjeti dio 4.5).
Aripiprazole exhibited high binding affinity in vitro for dopamine D2 and D3, serotonin 5HT1a and 5HT2a receptors and moderate affinity for dopamine D4, serotonin 5HT2c and 5HT7, alpha-1
Aripiprazol je in vitro pokazao visok afinitet vezanja za dopaminske D2 i D3, serotoninske 5HT1a i 5HT2a receptore i umjeren afinitet za dopaminske D4, serotoninske 5HT2c i 5HT7, alfa-1 adrenergičke i histaminske H1 receptore.
• in blood tests: fluctuating blood sugar, increased glycosylated haemoglobin.
• krvne pretrage: fluktuacija šećera u krvi, povišeni glikirani hemoglobin,
Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole.
Disfagija Poremećaj motiliteta jednjaka i aspiracija povezani su s primjenom antipsihotika, uključujući aripiprazol.
Concomitant administration of aripiprazole and other stronginducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John's Wort) may be expected to have similar effects and similar dose increases should therefore be applied.
Slični učinci mogu se očekivati i kod istodobne primjene aripiprazola i drugih induktora CYP3A4 (kao što su rifampicin, rifabutin, fenitoin, fenobarbital, primidon, efavirenz, nevirapin i gospina trava) pa se stoga moraju provesti slična povećanja doza.
Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35,for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.
Aripiprazol je pokazao poboljšanje na ljestvici TTS-YGTSS od početne vrijednosti do one u 8. tjednu od 13,35 u skupini koja je primala nisku dozu (5 mg ili 10 mg) i 16,94 u skupini koja je primala visoku dozu (10 mg ili 20 mg) u usporedbi s poboljšanjem od 7,09 u skupini koja je primala placebo.
Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (may affect more than 1 in 10 people) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (may affect up to 1 in 10 people).
Adolescenti u dobi od 13 ili više godina imali su nuspojave slične učestalosti i vrste kao i odrasli bolesnici, osim što su pospanost, nekontrolirano trzanje mišića ili trzajni pokreti, nemir i umor bili vrlo česti (mogu se javiti u više od 1 na 10 osoba), dok su bol u gornjem dijelu trbuha, suha usta, ubrzani otkucaji srca, povećanje tjelesne težine, pojačan apetit, trzanje mišića, nekontrolirani pokreti udova i osjećaj omaglice, osobito pri ustajanju iz ležećeg ili sjedećeg položaja, bili česti (mogu se javiti u do 1 na 10 osoba).
If you stop taking Aripiprazole Accord
Ako prestanete uzimati Aripiprazol Accord
Hydroxypropylcellulose Magnesium stearate Indigo carmine aluminium lake (E132)
Indigo carmine aluminium lake (E132)
• if you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in section 6).
Nemojte uzimati Aripiprazol Accord • ako ste alergični na aripiprazol ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
Blood pressure-lowering medicines: Aripiprazole Accord may increase the effect of medicines used to lower the blood pressure.
Accord može pojačati učinak lijekova koji se koriste za snižavanje krvnog tlaka.
Wessling Hungary, Anonymus u. 6., Budapest, 1045, Hungary
6., Budapest, 1045, Mađarska
Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.
Procjenom populacijske farmakokinetike nije se otkrio dokaz klinički značajnih učinaka pušenja na farmakokinetiku aripiprazola..
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava leukopenija neutropenija
In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13-17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39%) and placebo (37.50%) groups.
U randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju u trajanju od 60 do 89 tjedana u adolescentnih ispitanika (n = 146; u dobi od 13 do 17 godina) sa shizofrenijom postojala je statistički značajna razlika u stopi relapsa psihotičnih simptoma između skupine koja je primala aripiprazol (19,39%) i skupine koja je primala placebo (37,50%).
When concomitant administration of ketoconozole with aripiprazole occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose.
Kad se aripiprazol primjenjuje zajedno s ketokonazolom, doza aripiprazola mora se smanjiti na otprilike polovicu propisane doze.
Aripiprazole Accord 5/10/15/30 mg tablets are available in Aluminium/Aluminium perforated unit dose blister in pack-sizes of 14x1, 28x1, 49x1, 56x1 or 98x1 tablet.
Aripiprazol Accord 5/10/15/30 mg tablete dostupne su u aluminij/aluminij peforiranim blisterima djeljivim na jedinične doze u veličnama pakiranja od 14x1, 28x1, 49x1, 56x1 ili 98x1 tableta.
In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary end-point was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).
U 26-tjednom, olanzapinom kontroliranom, dvostruko slijepom, multinacionalnom ispitivanju shizofrenije koje je uključilo 314 odraslih bolesnika i gdje je primarna mjera ishoda bilo povećanje tjelesne težine, značajno manje bolesnika imalo je povećanje tjelesne težine od najmanje 7 % u odnosu na početnu vrijednost (tj. prirast od najmanje 5,6 kg na prosječnu početnu težinu od ~80,5 kg) u skupini na aripiprazolu (n = 18, ili 13 % bolesnika koji su se mogli procijeniti) u usporedbi sa skupinom koja je uzimala olanzapin (n = 45, ili 33 % bolesnika koji su se mogli procijeniti).
• a tendency to wander away.
sklonost da se odluta.
The safety profile of a long-term, double-blind placebo controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (≥ 1/100, <
Sigurnosni profil u dugotrajnom, dvostruko slijepom, placebom kontroliranom ispitivanju također je bio sličan, osim što su sljedeće nuspojave bile zabilježene češće nego u pedijatrijskih bolesnika koji su uzimali placebo: često (≥ 1/100, < 1/10) su bili zabilježeni smanjena tjelesna težina, povišen inzulin u krvi, aritmija i leukopenija.
Therefore, Aripiprazole Accord is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).
Accord ne preporučuje za primjenu u bolesnika mlađih od 13 godina (vidjeti dijelove 4.8 i
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
Krvožilni poremećaji ortostatska hipotenzija venska tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu) hipertenzija sinkopa
In a clinical trial in healthy subjects, a stronginhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and Cmax by 63 % and 37 %, respectively.
U kliničkim ispitivanjima sa zdravim ispitanicima, jaki inhibitor CYP3A4 (ketokonazol) povisio je AUC aripiprazola za 63 %, a Cmax za 37 %.
Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors, may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2).
Slični učinci mogu se očekivati i od drugih jakih inhibitora CYP3A4, kao što su itrakonazol i inhibitori HIV proteaze pa se stoga moraju provesti slična smanjenja doze (vidjeti dio 4.2).
When weak inhibitors of CYP3A4 (e.g., diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.
Kad se slabi inhibitori CYP3A4 (npr., diltiazem) ili CYP2D6 (npr. escitalopramkoriste istodobno s aripiprazolom , mogu se očekivati umjerena povišenja koncentracije aripiprazola u plazmi.
Aripiprazole Accord contains lactose.
Accord sadrži laktozu.
It has been proposed that aripiprazole's efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5HT1a receptors and antagonism of serotonin 5HT2a receptors.
I jest da je ono posredovano kombinacijom djelomičnog agonizma s dopaminskim D2 i serotoninskim 5HT1a receptorima i antagonizma sa serotoninskim 5HT2a receptorima.
A, aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).
Aripiprazol se mora koristiti s oprezom u bolesnika koji u obiteljskoj anamnezi imaju produljenje QT intervala (vidjeti dio 4.8).
Aripiprazole Accord 5/10/15 mg tablets are available in HDPE bottle with PPCRC closure containing 30 or 100 tablets.
Aripiprazol Accord 5/10/15 mg tablete dostupne su u HDPE boci s PPCRC čepom koja sadrži 30 ili 100 tableta.
In the pooled trials, the incidence of low serum prolactin levels in females (< 3 ng/ml) and males (< 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively.
U objedinjenim je ispitivanjima incidencija niske razine prolaktina u serumu u djevojčica (< 3 ng/ml) liječenih aripiprazolom iznosila 27/46 (58,7 %), a u dječaka (< 2 ng/ml) 258/298 (86,6 %).
Aripiprazole Accord 5/10/15/30 mg tablets are available in perforated unit dose blister packs (Aluminium/Aluminium) containing 14 x 1, 28 x 1, 49 x 1, 56 x 1, or 98 x 1 tablet.
Aripiprazol Accord 5/10/15/30 mg tablete dostupne su u peforiranim blisterima (aluminij/aluminij) djeljivim na jedinične doze u veličinama pakiranja od 14x1, 28x1, 49x1, 56x1 ili 98x1 tableta.
(for 30's count) HDPE bottle pack should be used within 100 days after first opening.
HDPE bocu treba iskoristiti u roku od 30 dana nakon prvog otvaranja. (za bocu s 30 tableta) HDPE bocu treba iskoristiti u roku od 100 dana nakon prvog otvaranja. (za bocu sa 100 tableta) Datum otvaranja: